416 related articles for article (PubMed ID: 24323984)
1. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).
Averbuch D; Cordonnier C; Livermore DM; Mikulska M; Orasch C; Viscoli C; Gyssens IC; Kern WV; Klyasova G; Marchetti O; Engelhard D; Akova M;
Haematologica; 2013 Dec; 98(12):1836-47. PubMed ID: 24323984
[TBL] [Abstract][Full Text] [Related]
2. Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon.
Ballouz T; Zeenny RM; Haddad N; Rizk N; Kanj SS
J Infect Dev Ctries; 2021 Sep; 15(9):1308-1313. PubMed ID: 34669601
[TBL] [Abstract][Full Text] [Related]
3. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.
Averbuch D; Orasch C; Cordonnier C; Livermore DM; Mikulska M; Viscoli C; Gyssens IC; Kern WV; Klyasova G; Marchetti O; Engelhard D; Akova M;
Haematologica; 2013 Dec; 98(12):1826-35. PubMed ID: 24323983
[TBL] [Abstract][Full Text] [Related]
4. Multidrug-resistant Gram-negative infections: what are the treatment options?
Giamarellou H; Poulakou G
Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic resistance in cancer patients.
Gudiol C; Carratalà J
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):1003-16. PubMed ID: 24834465
[TBL] [Abstract][Full Text] [Related]
6. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group.
Averbuch D; Tridello G; Hoek J; Mikulska M; Akan H; Yanez San Segundo L; Pabst T; Özçelik T; Klyasova G; Donnini I; Wu D; Gülbas Z; Zuckerman T; Botelho de Sousa A; Beguin Y; Xhaard A; Bachy E; Ljungman P; de la Camara R; Rascon J; Ruiz Camps I; Vitek A; Patriarca F; Cudillo L; Vrhovac R; Shaw PJ; Wolfs T; O'Brien T; Avni B; Silling G; Al Sabty F; Graphakos S; Sankelo M; Sengeloev H; Pillai S; Matthes S; Melanthiou F; Iacobelli S; Styczynski J; Engelhard D; Cesaro S
Clin Infect Dis; 2017 Nov; 65(11):1819-1828. PubMed ID: 29020364
[TBL] [Abstract][Full Text] [Related]
9. Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient.
Misch EA; Andes DR
Infect Dis Clin North Am; 2019 Jun; 33(2):399-445. PubMed ID: 31005135
[TBL] [Abstract][Full Text] [Related]
10. Establishing the role of tigecycline in an era of antimicrobial resistance.
Schafer JJ; Goff DA
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.
Guay DR
Pharmacotherapy; 2004 Jan; 24(1):58-68. PubMed ID: 14740788
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
Giamarellou H
Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
[TBL] [Abstract][Full Text] [Related]
14. Fosfomycin in antimicrobial stewardship programs.
Múñez Rubio E; Ramos Martínez A; Fernández Cruz A
Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):62-66. PubMed ID: 31131594
[TBL] [Abstract][Full Text] [Related]
15. Anaerobic infections: update on treatment considerations.
Nagy E
Drugs; 2010 May; 70(7):841-58. PubMed ID: 20426496
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016.
Dowzicky MJ; Chmelařová E
J Glob Antimicrob Resist; 2019 Jun; 17():44-52. PubMed ID: 30445209
[TBL] [Abstract][Full Text] [Related]
17. Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes.
Kaye KS; Gales AC; Dubourg G
Int J Antimicrob Agents; 2017 May; 49(5):542-548. PubMed ID: 28130072
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections.
Bassetti M; Pecori D; Cojutti P; Righi E; Pea F
Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1193-1200. PubMed ID: 28988505
[TBL] [Abstract][Full Text] [Related]
20. Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany.
Kresken M; Becker K; Seifert H; Leitner E; Körber-Irrgang B; von Eiff C; Löschmann PA;
Eur J Clin Microbiol Infect Dis; 2011 Sep; 30(9):1095-103. PubMed ID: 21347680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
